Listed in the December 27, 2023 extract; not in the current extract (Aug 26, 2026): Emo-Cort (00192597), Cortate (00502200), Emo-Cort (00192600). Source: odb-formulary-ed43-extract-2023-12-27.xml; compared with odb-formulary-ed43-extract-2026-08-26.xml.
HYDROCORTISONE
Form:
9 of 9 products shown
6 general benefit · 2 not a benefit · 1 listing conditions apply
Other products in the same Health Canada class (H02AB) — coverage varies; not interchangeable
Dexamethasone (Decadron): general benefit, Not a benefit
Dexamethasone (Decadron): general benefit, Not a benefit
Methylprednisolone (Medrol): general benefit
Methylprednisolone (Depo-Medrol): general benefit
Prednisolone (Pediapred Oral Liquid): general benefit, Not a benefit
Prednisone (Winpred): general benefit, Not a benefit
14 more in the class list below
Auro-Hydrocortisone · DIN 02524465 · 10mg · tablet
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Auro-Hydrocortisone · DIN 02524465
Manufacturer: Auro Pharma Inc.; listing date 2023-06-30
Health Canada: Marketed since 2022-11-22 · brand AURO-HYDROCORTISONE · ATC H02AB09 HYDROCORTISONE · form Tablet · route Oral · ingredients HYDROCORTISONE 10 MG · company Auro pharma inc · schedule Prescription
Auro-Hydrocortisone: Formulary list price $0.1639/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.1639 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101351 · Verify on the e-Formulary ↗ (DIN 02524465)
Source record
DIN 02524465: Auro-Hydrocortisone
Raw flags: sec3=Y
Item: 680400057; group id 712; item number 1760; lccId None; manufacturer id AUR
Source form: Tab; strength: 10mg
Recorded listing: General benefit
Source prices (unrounded): $0.1639; ministry $0.1639
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02524465
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101351Interchangeable products
Cortef · DIN 00030910 · $0.1639
Shortage status: resolved shortage (ended 2026-04-21); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02524465
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Cortef · DIN 00030910 · 10mg · tablet
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Cortef · DIN 00030910
Manufacturer: Pfizer Canada Inc.; listing date 2003-09-04
Health Canada: Marketed since 2005-06-21 · brand CORTEF · ATC H02AB09 HYDROCORTISONE · form Tablet · route Oral · ingredients HYDROCORTISONE 10 MG · company Pfizer canada ulc · schedule Prescription
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=432 · Verify on the e-Formulary ↗ (DIN 00030910)
Source record
DIN 00030910: Cortef
Raw flags: sec3=Y
Item: 680400057; group id 712; item number 1760; lccId None; manufacturer id PFI
Source form: Tab; strength: 10mg
Recorded listing: General benefit
Source prices (unrounded): $0.2301; ministry $0.1639
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00030910
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=432Interchangeable products
Auro-Hydrocortisone · DIN 02524465 · $0.1639
Shortage status: resolved shortage (ended 2023-02-23); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=00030910
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Auro-Hydrocortisone · DIN 02524473 · 20mg · tablet
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Auro-Hydrocortisone · DIN 02524473
Manufacturer: Auro Pharma Inc.; listing date 2023-06-30
Health Canada: Marketed since 2022-11-22 · brand AURO-HYDROCORTISONE · ATC H02AB09 HYDROCORTISONE · form Tablet · route Oral · ingredients HYDROCORTISONE 20 MG · company Auro pharma inc · schedule Prescription
Auro-Hydrocortisone: Formulary list price $0.2958/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.2958 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101352 · Verify on the e-Formulary ↗ (DIN 02524473)
Source record
DIN 02524473: Auro-Hydrocortisone
Raw flags: sec3=Y
Item: 680400007; group id 712; item number 1762; lccId None; manufacturer id AUR
Source form: Tab; strength: 20mg
Recorded listing: General benefit
Source prices (unrounded): $0.2958; ministry $0.2958
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02524473
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=101352Interchangeable products
Cortef · DIN 00030929 · $0.2958
Shortage status: resolved shortage (ended 2026-04-20); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02524473
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Cortef · DIN 00030929 · 20mg · tablet
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Cortef · DIN 00030929
Manufacturer: Pfizer Canada Inc.; listing date 1996-10-01
Health Canada: Marketed since 2005-05-27 · brand CORTEF · ATC H02AB09 HYDROCORTISONE · form Tablet · route Oral · ingredients HYDROCORTISONE 20 MG · company Pfizer canada ulc · schedule Prescription
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=433 · Verify on the e-Formulary ↗ (DIN 00030929)
Source record
DIN 00030929: Cortef
Raw flags: sec3=Y
Item: 680400007; group id 712; item number 1762; lccId None; manufacturer id PFI
Source form: Tab; strength: 20mg
Recorded listing: General benefit
Source prices (unrounded): $0.4155; ministry $0.2958
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00030929
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=433Interchangeable products
Auro-Hydrocortisone · DIN 02524473 · $0.2958
Shortage status: resolved shortage (ended 2023-02-15); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=00030929
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Cortoderm · PIN 00716685 · 0.5% · Oint
General benefitOntario PIN; no Health Canada record under this code
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
No Health Canada record under this code: Ontario lists it under a product identification number (PIN), not a DIN.
Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Cortoderm · DIN 00716685
Manufacturer: Taro Pharmaceuticals Inc.; listing date 1996-10-01
No Health Canada record under this code: Ontario lists it under a product identification number (PIN), not a DIN.
Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp
DIN 00716685: Cortoderm
Raw flags: sec3=Y
Item: 840600027; group id 846; item number 2059; lccId None; manufacturer id TAR
Source form: Oint; strength: 0.5%
Recorded listing: General benefit
Source prices (unrounded): $0.1400; ministry $0.1400
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00716685
Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jspInterchangeable products
Cortate · DIN 00513261 · not recorded
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=00716685
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Cortoderm · PIN 00716693 · 1% · Oint
General benefitOntario PIN; no Health Canada record under this code
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
No Health Canada record under this code: Ontario lists it under a product identification number (PIN), not a DIN.
Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Cortoderm · DIN 00716693
Manufacturer: Taro Pharmaceuticals Inc.; listing date 1996-10-01
No Health Canada record under this code: Ontario lists it under a product identification number (PIN), not a DIN.
Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp
DIN 00716693: Cortoderm
Raw flags: sec3=Y
Item: 840600026; group id 846; item number 2060; lccId None; manufacturer id TAR
Source form: Oint; strength: 1%
Recorded listing: General benefit
Source prices (unrounded): $0.0390; ministry $0.0390
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00716693
Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jspInterchangeable products
Cortate · DIN 00502197 · not recorded
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=00716693
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Cortef · PIN 09858155 · 10mg · tablet
Temporary benefitOntario PIN; no Health Canada record under this code
StatusTemporary benefit
Write on scriptcheck temporary-benefit rules below
Patient paysPatient pays: program not supplied; amount cannot be determined.
No Health Canada record under this code: Ontario lists it under a product identification number (PIN), not a DIN.
Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
No interchangeable product listed in the Ontario extract
Cortef · DIN 09858155
Manufacturer: Pfizer Canada Inc.; listing date 2022-06-30
No Health Canada record under this code: Ontario lists it under a product identification number (PIN), not a DIN.
Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp
DIN 09858155: Cortef
Raw flags: sec3c=Y
Item: 680400123; group id 712; item number 1761; lccId None; manufacturer id PFI
Source form: Tab; strength: 10mg
Recorded listing: Temporary benefit (shortage substitute)
Source prices (unrounded): $0.2185; ministry $0.2185
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=09858155
Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=09858155
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Cortate · PIN 00513261 · 0.5% · Oint
Listed, not a benefitOntario PIN; no Health Canada record under this code
StatusListed, not a benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
No Health Canada record under this code: Ontario lists it under a product identification number (PIN), not a DIN.
Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Cortate · DIN 00513261
Manufacturer: Schering Canada Inc.; listing date 1996-10-01
No Health Canada record under this code: Ontario lists it under a product identification number (PIN), not a DIN.
Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp
DIN 00513261: Cortate
Raw flags: notABenefit=Y, sec3=Y
Item: 840600027; group id 846; item number 2059; lccId None; manufacturer id SCH
Source form: Oint; strength: 0.5%
Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category
Source prices (unrounded): not recorded; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00513261
Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jspInterchangeable products
Cortoderm · DIN 00716685 · $0.1400
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=00513261
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Cortate · DIN 00502197 · 1% · Oint
Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2013-07-31 — choose a marketed DIN from the same-category list.Discontinued 2013-07-31 · checked 2026-09-02
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2013-07-31 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2013-07-31 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Cortate · DIN 00502197
Manufacturer: Schering Canada Inc.; listing date 1996-10-01
Health Canada: Cancelled post market since 2013-07-31 · brand CORTATE ONT 1% · ATC D07AA02 HYDROCORTISONE · form Ointment · route Topical · ingredients HYDROCORTISONE 10 MG/G · company Schering-plough canada inc · schedule Prescription
Cortate: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=3880 · Verify on the e-Formulary ↗ (DIN 00502197)
Source record
DIN 00502197: Cortate
Raw flags: notABenefit=Y, sec3=Y
Item: 840600026; group id 846; item number 2060; lccId None; manufacturer id SCH
Source form: Oint; strength: 1%
Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category
Source prices (unrounded): not recorded; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00502197
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=3880Interchangeable products
Cortoderm · DIN 00716693 · $0.0390
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=00502197
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2013-07-31 — choose a marketed DIN from the same-category list.
HYDROCORTISONE ACETATE
1 general benefit · 1 not a benefit
Other products in the same Health Canada class (H02AB) — coverage varies; not interchangeable
Dexamethasone (Decadron): general benefit, Not a benefit
Dexamethasone (Decadron): general benefit, Not a benefit
Methylprednisolone (Medrol): general benefit
Methylprednisolone (Depo-Medrol): general benefit
Prednisolone (Pediapred Oral Liquid): general benefit, Not a benefit
Prednisone (Winpred): general benefit, Not a benefit
14 more in the class list below
Hyderm · PIN 00716839 · 1% · Cr
General benefitOntario PIN; no Health Canada record under this code
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
No Health Canada record under this code: Ontario lists it under a product identification number (PIN), not a DIN.
Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Hyderm · DIN 00716839
Manufacturer: Taro Pharmaceuticals Inc.; listing date 1996-10-01
No Health Canada record under this code: Ontario lists it under a product identification number (PIN), not a DIN.
Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jsp
DIN 00716839: Hyderm
Raw flags: sec3=Y
Item: 840600077; group id 847; item number 2061; lccId None; manufacturer id TAR
Source form: Cr; strength: 1%
Recorded listing: General benefit
Source prices (unrounded): $0.2056; ministry $0.2056
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00716839
Look up the brand's own DIN on Health Canada: https://health-products.canada.ca/dpd-bdpp/index-eng.jspInterchangeable products
Corticreme · DIN 00477699 · not recorded
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=00716839
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Corticreme · DIN 00477699 · 1% · Cr
Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 1999-09-27 — choose a marketed DIN from the same-category list.Discontinued 1999-09-27 · checked 2026-09-02
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 1999-09-27 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 1999-09-27 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Corticreme · DIN 00477699
Manufacturer: Rougier Pharma, Division of Ratiopharm Inc.; listing date 1996-10-01
Health Canada: Cancelled post market since 1999-09-27 · brand CORTICREME 1% · ATC D07AA02 HYDROCORTISONE · form Cream · route Topical · ingredients HYDROCORTISONE ACETATE 10 MG/G · company Rougier pharma division of ratiopharm inc · schedule Prescription
Corticreme: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=3894 · Verify on the e-Formulary ↗ (DIN 00477699)
Source record
DIN 00477699: Corticreme
Raw flags: notABenefit=Y, sec3=Y
Item: 840600077; group id 847; item number 2061; lccId None; manufacturer id ROG
Source form: Cr; strength: 1%
Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category
Source prices (unrounded): not recorded; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=00477699
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=3894Interchangeable products
Hyderm · DIN 00716839 · $0.2056
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=00477699
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 1999-09-27 — choose a marketed DIN from the same-category list.
HYDROCORTISONE VALERATE
Form:
4 of 4 products shown
2 general benefit · 2 not a benefit
Other products in the same Health Canada class (H02AB) — coverage varies; not interchangeable
Dexamethasone (Decadron): general benefit, Not a benefit
Dexamethasone (Decadron): general benefit, Not a benefit
Methylprednisolone (Medrol): general benefit
Methylprednisolone (Depo-Medrol): general benefit
Prednisolone (Pediapred Oral Liquid): general benefit, Not a benefit
Prednisone (Winpred): general benefit, Not a benefit
14 more in the class list below
Hydroval · DIN 02242984 · 0.2% · Cr
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Hydroval · DIN 02242984
Manufacturer: TaroPharma, a Division of Taro Pharmaceuticals Inc.; listing date 2001-10-11
Health Canada: Marketed since 2004-03-30 · brand HYDROVAL CREAM 0.2% · ATC D07AA02 HYDROCORTISONE · form Cream · route Topical · ingredients HYDROCORTISONE VALERATE 0.2 % · company Taropharma, a division of taro pharmaceuticals inc. · schedule Prescription
Hydroval: Formulary list price $0.1667/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.1667 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=66824 · Verify on the e-Formulary ↗ (DIN 02242984)
Source record
DIN 02242984: Hydroval
Raw flags: sec3=Y
Item: 840600060; group id 848; item number 2062; lccId None; manufacturer id TPH
Source form: Cr; strength: 0.2%
Recorded listing: General benefit
Source prices (unrounded): $0.1667; ministry $0.1667
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02242984
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=66824Interchangeable products
Westcort · DIN 01910124 · not recorded
Shortage status: resolved shortage (ended 2022-09-07); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02242984
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Hydroval · DIN 02242985 · 0.2% · Oint
General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Hydroval · DIN 02242985
Manufacturer: TaroPharma, a Division of Taro Pharmaceuticals Inc.; listing date 2001-10-11
Health Canada: Marketed since 2004-04-06 · brand HYDROVAL OINTMENT 0.2% · ATC D07AA02 HYDROCORTISONE · form Ointment · route Topical · ingredients HYDROCORTISONE VALERATE 0.2 % · company Taropharma, a division of taro pharmaceuticals inc. · schedule Prescription
Hydroval: Formulary list price $0.1667/unit (unit not stated in source; not the patient's cost)
Ministry pays: $0.1667 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=66825 · Verify on the e-Formulary ↗ (DIN 02242985)
Source record
DIN 02242985: Hydroval
Raw flags: sec3=Y
Item: 840600084; group id 848; item number 2063; lccId None; manufacturer id TPH
Source form: Oint; strength: 0.2%
Recorded listing: General benefit
Source prices (unrounded): $0.1667; ministry $0.1667
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02242985
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=66825Interchangeable products
Westcort · DIN 01910132 · not recorded
Shortage status: resolved shortage (ended 2022-12-22); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02242985
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Westcort · DIN 01910124 · 0.2% · Cr
Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2006-12-18 — choose a marketed DIN from the same-category list.Discontinued 2006-12-18 · checked 2026-09-02
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2006-12-18 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2006-12-18 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Westcort · DIN 01910124
Manufacturer: Bristol Myers Squibb Canada Inc; listing date 1996-10-01
Health Canada: Cancelled post market since 2006-12-18 · brand WESTCORT CRM 0.2% · ATC D07AA02 HYDROCORTISONE · form Cream · route Topical · ingredients HYDROCORTISONE VALERATE 0.2 % · company Westwood-squibb, division of bristol-myers squibb canada inc. · schedule Prescription
Westcort: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=12236 · Verify on the e-Formulary ↗ (DIN 01910124)
Source record
DIN 01910124: Westcort
Raw flags: notABenefit=Y, sec3=Y
Item: 840600060; group id 848; item number 2062; lccId None; manufacturer id BQU
Source form: Cr; strength: 0.2%
Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category
Source prices (unrounded): not recorded; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=01910124
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=12236Interchangeable products
Hydroval · DIN 02242984 · $0.1667
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=01910124
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2006-12-18 — choose a marketed DIN from the same-category list.
Westcort · DIN 01910132 · 0.2% · Oint
Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2009-04-17 — choose a marketed DIN from the same-category list.Discontinued 2009-04-17 · checked 2026-09-02
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2009-04-17 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives; Health Canada lists this DIN as Cancelled post market since 2009-04-17 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Westcort · DIN 01910132
Manufacturer: Bristol Myers Squibb Canada Inc; listing date 1996-10-01
Health Canada: Cancelled post market since 2009-04-17 · brand WESTCORT ONT 0.2% · ATC D07AA02 HYDROCORTISONE · form Ointment · route Topical · ingredients HYDROCORTISONE VALERATE 0.2 % · company Westwood-squibb, division of bristol-myers squibb canada inc. · schedule Prescription
Westcort: Formulary list price not recorded/unit (unit not stated in source; not the patient's cost)
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=11946 · Verify on the e-Formulary ↗ (DIN 01910132)
Source record
DIN 01910132: Westcort
Raw flags: notABenefit=Y, sec3=Y
Item: 840600084; group id 848; item number 2063; lccId None; manufacturer id BQU
Source form: Oint; strength: 0.2%
Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category
Source prices (unrounded): not recorded; ministry not recorded
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=01910132
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=11946Interchangeable products
Hydroval · DIN 02242985 · $0.1667
Shortage status: no shortage or discontinuation reported (checked 2026-09-13T08:10:21.292534+00:00); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=01910132
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2009-04-17 — choose a marketed DIN from the same-category list.
Other drugs in the same formulary classes and how they are covered
Other drugs in the same formulary class (68:04 Corticosteroids) and how they are covered
Matched class: 68:04 Corticosteroids
Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment.
Covered without a code on the Ontario formulary: BECLOMETHASONE DIPROPIONATE, CICLESONIDE, FLUDROCORTISONE ACETATE, FLUTICASONE FUROATE, FLUTICASONE PROPIONATE, METHYLPREDNISOLONE, METHYLPREDNISOLONE ACETATE, MOMETASONE FUROATE, TRIAMCINOLONE ACETONIDE
Some products covered without a code (check the product listing): BUDESONIDE, DEXAMETHASONE, DEXAMETHASONE 21-PHOSPHATE, PREDNISOLONE SODIUM PHOSPHATE, PREDNISONE
68:04 Corticosteroids
Other drugs in the same formulary class (84:06 Anti-Inflammatory) and how they are covered
Matched class: 84:06 Anti-Inflammatory
Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment.
Covered without a code on the Ontario formulary: BECLOMETHASONE DIPROPIONATE, BETAMETHASONE DIPROPIONATE IN A BASE CONTAINING PROPYLENE GLYCOL, BETAMETHASONE DIPROPIONATE IN PROPYLENE GLYCOL BASE, CALCIPOTRIOL & BETAMETHASONE DIPROPIONATE, HALOBETASOL PROPIONATE, MOMETASONE FUROATE
Some products covered without a code (check the product listing): AMCINONIDE, BETAMETHASONE DIPROPIONATE, BETAMETHASONE VALERATE, CLOBETASOL PROPIONATE, DESONIDE, FLUOCINONIDE, TRIAMCINOLONE ACETONIDE, TRIAMCINOLONE ACETONIDE 0.1% IN ORABASE
84:06 Anti-Inflammatory
· 6 products · General benefit (5), General benefit; DIN status E (meaning unconfirmed); confirm discontinuation/availability with Health Canada (1) · strengths: 0.05% · Cr, Lot, Oint
· 20 products · General benefit (11), Off-Formulary Interchangeable, not an ODB benefit (9) · strengths: 0.05%, 0.05% w/w · Cr, Oint, Scalp Lot, Top Shampoo, Top Sol Sp
· 5 products · Listed, not a benefit (3), General benefit (2) · strengths: 0.1% · Cr, Oint
Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 84:06
and 3 more
From Health Canada product monographs; label wording only, not a treatment recommendation.
Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ.
Covered without a code on the Ontario formulary: METHYLPREDNISOLONE
METHOTREXATE · General benefit (29), Listed, not a benefit (1), Off-Formulary Interchangeable, not an ODB benefit (4)
1 INDICATIONS
pms-METHOTREXATE is indicated for Neoplastic diseases:
• Choriocarcinoma: Methotrexate – as single chemotherapy or in combination with other drugs.
PM: https://pdf.hres.ca/dpd_pm/00078227.PDF; date JAN 08, 2025; DIN 02170698; fetched 2026-09-10
Product monographMETHYLPREDNISOLONE · General benefit
1. Endocrine Disorders
PM: https://pdf.hres.ca/dpd_pm/00080809.PDF; date 2025-06-13; DIN 00030988; fetched 2026-09-10
Product monograph
Coverage source: ON formulary extract 2026-08-26
What the Health Canada label says it is for
1 Indications
CORTEF (hydrocortisone) is indicated for:
• Endocrine Disorders: Primary or secondary adrenocortical insufficiency (hydrocortisone or
cortisone is the first choice; synthetic analogs may be used in conjunction with mineralocorticoids
where applicable; in infancy, mineralocorticoid supplementation is of particular importance);
congenital adrenal hyperplasia; nonsuppurative thyroiditis; hypercalcemia associated with cancer.
• Rheumatic Disorders: As adjunctive therapy for short term administration (to tide the patient over
an acute episode or exacerbation) in: psoriatic arthritis, rheumatoid arthritis, including juvenile
rheumatoid arthritis (selected cases may require low dose maintenance therapy), ankylosing
spondylitis, acute and subacute bursitis, acute nonspecific tenosynovitis, acute gouty arthritis,
posttraumatic osteoarthritis, synovitis of osteoarthritis, epicondylitis.
• Collagen Diseases: During an exacerbation or as maintenance therapy in selected cases of:
systemic lupus erythematosus, acute rheumatic carditis, systemic dermatomyositis (polymyositis).
• Dermatologic Diseases: pemphigus, bullous der…
https://pdf.hres.ca/dpd_pm/00082414.PDF
PM date: OCT 20, 2025
Source product: CORTEF; DIN 00030910; fetched 2026-09-10
Product monograph posted by Health Canada; excerpt for lookup only.
What the Health Canada label says it is for
Product monograph unavailable: no marketed product found
What the Health Canada label says it is for
INDICATIONS AND CLINICAL USE
HydroVal 0.2% (hydrocortisone valerate) cream and ointment are indicated for
topical therapy of acute and chronic corticosteroid responsive dermatoses, where
an anti-inflammatory, anti-allergenic and antipruritic activity is required in the
topical management of these conditions.
https://pdf.hres.ca/dpd_pm/00006434.PDF
PM date: not printed or not captured
Source product: HYDROVAL CREAM 0.2%; DIN 02242984; fetched 2026-09-10
Product monograph posted by Health Canada; excerpt for lookup only.
Other review policies
For Cortate, Corticreme, Westcort: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.
For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy
Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.
For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)
Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.